Matthew Voorsanger, MD
Cardiovascular Disease · Poulsbo, WANPI 1073506143
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 36.9% of the total. Reporting peaked in 2024 at $43 and has fallen 51.4% since, to $21 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in WA, where the typical reported total is $606.
Across 5 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$42
- E.r. Squibb & Sons, L.L.C.$31
- Boston Scientific$21
- Kestra Medical Technology Services, Inc.$20
What the payments were for
- Food & beverage$113100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 1 | $31 |
| Boston Scientific | 1 | $21 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
How this compares
$113 in reported general payments places this provider in the 15th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 299 | $417,285 |
| XareltoRivaroxaban | 133 | $175,927 |
| JardianceEmpagliflozin | 57 | $79,917 |
| Repatha SureclickEvolocumab | 42 | $53,795 |
| EntrestoSacubitril/Valsartan | 42 | $49,676 |
| Praluent PenAlirocumab | 17 | $11,675 |
| BrilintaTicagrelor | 16 | $11,269 |
| Metoprolol Succinate | 537 | $9,715 |
| SavaysaEdoxaban Tosylate | 11 | $4,498 |
| Torsemide | 101 | $3,714 |
| Atorvastatin Calcium | 352 | $3,633 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 119 | $3,519 |
| Losartan Potassium | 331 | $2,985 |
| Rosuvastatin Calcium | 234 | $2,967 |
| Telmisartan | 37 | $1,999 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Poulsbo
- Robert BersinBellevue$657K
- Mariko HarperSeattle$246K
- Gary OppenheimSeattle$153K
- Kelley BranchSeattle$103K
- Munish Kumar KannabhiranRichland$85K
- Erik WissnerSeattle$67K
- Younghoon KwonSeattle$66K
- Thomas AmidonBellevue$64K
- Aron BenderSeattle$60K
- Vidhushei YogeswaranSeattle$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.